Form 4: Stoke Therapeutics' Chief Medical Officer Reports Stock Transactions

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, reports the acquisition of common stock through the vesting of restricted stock units.

Summary

• On March 15, 2025, Barry Ticho, the Chief Medical Officer of Stoke Therapeutics, acquired 13,100 shares of common stock through the vesting of restricted stock units (RSUs).
• Additionally, Ticho acquired 10,000 shares of common stock through the vesting of additional RSUs on the same date.
• The price per share for both transactions was $0, indicating they were related to the vesting of previously granted equity awards.
• Following these transactions, Ticho directly owns 57,846 shares and 67,846 shares of Stoke Therapeutics common stock.
• Ticho also holds 26,200 and 30,000 derivative securities in the form of restricted stock units.

Sentiment

Score: 5

Explanation: This is a routine filing related to executive compensation. It doesn't contain information that would significantly shift investor sentiment.

Positives

• The vesting of RSUs indicates that the executive is meeting the conditions of their equity grants, which is generally tied to continued service to the company.

Industry Context

Form 4 filings are a routine part of the equity compensation process for publicly traded companies. They provide transparency into the transactions of company insiders.

Stakeholder Impact

• The vesting of RSUs dilutes existing shareholders' equity slightly.

Key Dates